The US Food and Drug Administration (FDA) has recently issued an Emergency Use
Authorization (EUA) for 2 highly effective coronavirus disease 2019 (COVID-19) vaccines …

Concerns for anaphylaxis may hamper severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) immunization efforts. We convened a multidisciplinary group of international …

Background Cutaneous reactions after messenger RNA (mRNA)-based COVID-19 vaccines
have been reported but are not well characterized. Objective To evaluate the morphology …

Delayed Local Reactions to mRNA-1273 Vaccine Delayed cutaneous reactions developed
in 12 patients days after initial injection-related symptoms resolved. The reactions, some as …

Background The Centers for Disease Control and Prevention state that a severe or
immediate allergic reaction to the first dose of an mRNA COVID-19 vaccine is a …

Background Anaphylaxis, which is rare, has been reported after COVID‐19 vaccination, but
its management is not standardized. Method Members of the European Network for Drug …

Allergists and clinical immunologists around the world are increasingly faced with the task of
addressing drug allergy and hypersensitivity due to the increase in drug reactions …

This report updates the 2018–19 recommendations of the Advisory Committee on
Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines in the …

When drug reactions resembling allergy occur, they are called drug hypersensitivity
reactions (DHR s) before showing the evidence of either drug‐specific antibodies or T cells …

Vaccination continues to be the single most important and successful public health
intervention, due to its prevention of morbidity and mortality from prevalent infectious …